Market Overview

Global Cancer Immunotherapies Market 2018-2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline -


The "Global
Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune
Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust
report has been added to's

The report focuses on the key indications of breast cancer, leukemia,
lymphoma, melanoma and non-small cell lung cancer, these indications are
the largest in terms of size, with 448, 526, 456, 415 and 374 in active
development, respectively. The pipeline is dominated mAbs, cell
therapies, small molecules and cancer vaccines.

Cancer immunotherapy, which can predominantly be classed as a form of
targeted therapy, drives an immune response against cancer cells. This
may include stimulating a patient's immune system in a general way or
aiding the identification of specific antigens associated with the

The interest in cancer immunotherapy development has been driven by the
growing understanding of the immune system as a hallmark of cancer
pathophysiology, particularly immune evasion of developing cancer cells.
Overall, 3,863 products are being actively developed in the cancer
immunotherapy pipeline, approximately half of the overall oncology


  • Global revenue from the cancer immunotherapies market is forecast to
    increase from $33.7 billion in 2017 to $103.4 billion in 2024, at a
    compound annual growth rate of 17.4%. What is driving this growth?
  • The leading companies in terms of market share are Celgene, Merck &
    Co., Bristol-Myers Squibb and Roche. Which of these are forecast to
    experience the largest growth?
  • There are some key new approvals and late-stage products set to enter
    the market during the forecast period. Which impact will these drugs
    have on the market?
  • The market has been dominated by immune checkpoint inhibitors and
    drugs that target tumor associated antigens. To what extent will these
    classes of drugs and others dominate the market over the forecast
  • There are 3,863 cancer immunotherapy products in the pipeline. What
    molecular targets are most abundant in the pipeline and what role will
    pipeline product approvals play in market growth?
  • Cancer immunotherapy clinical trials have an overall attrition rate of
    around 96%, what can companies do to maximize their chance of success?

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Key Marketed Products

4 Pipeline Landscape Assessment

5 Multi-scenario Market Forecast to 2024

6 Company Analysis and Positioning

7 Strategic Consolidations

8 Appendix

Companies Featured

  • AbbVie
  • Advaxis
  • Amgen
  • AstraZeneca
  • Biogen
  • Bristol-Myers Squibb
  • Celgene
  • Gilead Sciences
  • Incyte Corp
  • Johnson & Johnson
  • Juno Therapeutics
  • Merck & Co.
  • Novartis
  • Ono Pharma
  • Regeneron/Sanofi
  • Roche

For more information about this report visit

View Comments and Join the Discussion!